Outcome of classical Hodgkin’s lymphoma treatment over ten-year period in Novosibirsk

Abstract

Aim of the research. To assess the long-term results of therapy over 10 years in patients with classical Hodgkin’s lymphoma (cHL) in Novosibirsk.
Materials and Methods. The study included 362 patients with cHL who were followed up in the Hematology Department of the City Clinical Hospital No. 2 in Novosibirsk from January 2008 to December 2018.
Results. Ten-year and 5-year overall survival (OS) in patients with early-stage (I and II) cHL was 95.1 and 98% respectively, in patients with stages III and IV — 89.2 and 90.5% respectively. Relapse-free survival (RFS) of the I and II stage patients was equal to 85%, while in patients with stage III and IV — 66.5% (p = 0.01). The survival rates of patients with cHL with a favorable prognosis within 5 and 10 years after treatment were equal to 100%, while in patients with a poor prognosis these values were 91.7 and 88.9% respectively. Five-year RFS in patients with a favorable prognosis was 95%, ten-year RFS — 91%, in patients with a poor prognosis — 80.8 and 70% respectively (p = 0.001).
Conclusion. The findings indicate a high percentage of survival in patients with cHL and are comparable with the results of other research teams. Thus, the indicators of 5-year overall and relapse-free survival when using combined methods exceed 95 and 80% respectively. Determination of the prospects for improving treatment results dictates the need to continue further scientific search for optimal risk-adapted cHL treatment regimens.